Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Advicor | Niacin/lovastatin | Hypercholesterolemia and mixed dyslipidemia | List | Complete | ||
| Macugen | Pegaptanib sodium | Macular degeneration, age-related | Do not list | Complete | ||
| Raptiva | Efalizumab | Psoriasis, moderate to severe chronic plaque | List with clinical criteria and/or conditions | Complete | ||
| Norprolac | Quinagolide hydrochloride | Hyperprolactinemia | List with clinical criteria and/or conditions | Complete | ||
| Aptivus | Tipranavir | HIV infection | List with clinical criteria and/or conditions | Complete | ||
| Caduet | Amlodipine besylate/ atorvastatin calcium | Hypertension/ Dyslipidemia | List with clinical criteria and/or conditions | Complete | ||
| Levemir | Insulin detemir | Diabetes mellitus | Do not list | Complete | ||
| Somavert | Pegvisomant | acromegaly | Do not list | Complete | ||
| Remodulin | Treprostinil sodium | Pulmonary arterial hypertension (NYHA Class III and IV patients) | List with clinical criteria and/or conditions | Complete | ||
| Trelstar | Triptorelin pamoate | Cancer, prostate | List in a similar manner to other drugs in class | Complete |
Last Updated : April 27, 2024